Paragon Associates & Paragon Associates Ii Joint Venture Dia Medica Therapeutics Inc. Call Options Transaction History
Paragon Associates & Paragon Associates Ii Joint Venture
- $54 Million
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding DMAC
# of Institutions
42Shares Held
4.22MCall Options Held
8.2KPut Options Held
200-
Vanguard Group Inc Valley Forge, PA1.05MShares$4.31 Million0.0% of portfolio
-
First Manhattan CO New York, NY839KShares$3.45 Million0.01% of portfolio
-
Bleichroeder LP New York, NY382KShares$1.57 Million0.54% of portfolio
-
Geode Capital Management, LLC Boston, MA307KShares$1.26 Million0.0% of portfolio
-
Jacob Asset Management Of New York LLC Hermosa Beach, CA169KShares$693,4800.62% of portfolio
About DiaMedica Therapeutics Inc.
- Ticker DMAC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 26,443,100
- Market Cap $109M
- Description
- DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type...